New drug may offer safer option for Hormone-Driven high blood pressure
NCT ID NCT07688928
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study tests whether a newer drug, finerenone, works better and is safer than the standard drug spironolactone for people with high blood pressure due to primary aldosteronism—a condition where the adrenal glands make too much of the hormone aldosterone. About 104 adults with this condition will receive either finerenone or spironolactone for 48 weeks, with doses adjusted to reach target blood pressure and hormone levels. The trial measures how quickly and at what dose each drug achieves control, along with effects on kidney function, heart structure, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Finerenone
- What this could lead to
- If finerenone works better or has fewer side effects than spironolactone, it could become a new standard treatment for primary aldosteronism.
- What could go wrong
- This is a single-center trial with 104 participants, so results may not apply broadly. Both drugs can cause high potassium levels or kidney issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 104 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age \>18 years. 2. History of hypertension (blood pressure \>140/90 mm Hg), both newly detected and already established patients. 3. Diagnosed case of primary aldosteronism (PA) based on a screening test (increased aldosterone renin ration (ARR) \>70pmol/L) and confirmed by saline suppression test (post-saline PAC \>170pmol/L, where PAC measured by immunoassay). 4. Serum potassium ≥2.5 mmol/L. Exclusion Criteria: 1. Uncontrolled hypertension (\>180/120 mm Hg). 2. Lateralized PA patients (aldosterone producing adenoma or unilateral hyperplasia) who want to undergo adrenalectomy or having aldosterone producing carcinoma. 3. Participants already with mineralocorticoid receptor antagonist treatment. 4. Patients receiving medications confounding PAC or PRC (glucocorticoids, sodium glucose co-transporter 2 inhibitors (SGLT-2i) or systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors (e.g. itraconazole, clarithromycin, rifampicin, carbamazepine, phenytoin, phenobarbital, efavirenz) that cannot be discontinued 14 days prior to randomization or for the duration of treatment period. 5. Abnormal renal function test: eGFR \<60 ml/min-1.73m2. 6. Serum potassium level \>5 mmol/L. 7. Recent cardiovascular events like acute myocardial ischemia, heart failure with hospitalization, stroke or transient ischemic attack ≤3 months before the screening visit. 8. Uncontrolled DM (HbA1C \>12%) 9. Hepatic insufficiency (Child-Pugh C) 10. Addison's disease 11. Pregnant and lactating women. Women with child bearing potential must agree to use adequate contraception during and until 2 month of the end of study period. 12. Patient with other form of secondary HTN (e.g. renovascular HTN, Cushing syndrome, pheochromocytoma, coarctation of aorta etc.) 13. Known hypersensitivity to the study drugs. 14. Patients unwilling to participate in this study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Endocrine hypertension are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Endocrine HTN Clinic
RECRUITINGDhaka, 1000, Bangladesh
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill quiet the adrenal Glands' hormone overdrive?
- Sauna bathing may offer a sweat-based path to lower blood pressure
- Can a new PET scan light up hidden adrenal tumors causing high blood pressure?
- Wearable tech puts hormone health to the test
- New scan could replace risky vein test for Hormone-Driven high blood pressure
- New screening strategy could speed diagnosis of inherited aldosteronism